Skip to main content

Table 1 ADAM10 expression level before and after neoadjuvant chemotherapy (NACT) in Cohort 1 and Cohort 2 according to different chemotherapy response

From: ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

  Pre-NACT (mean ± SE) Post-NACT (mean ± SE) p-value
Cohort 1 (n = 25) 172.4 ± 77.18 118.4 ± 86.98 0.039*
Cohort 2 (n = 69) 129.1 ± 88.04 170.6 ± 94.49 0.030*
p-value 0.023* 0.020*  
  1. Cohort 1: Samples showing poor response to NACT
  2. Cohort 2: Samples showing good response to NACT
  3. *p < 0.05, **p < 0.01